Weekly Dose of Optimism #195
Not Boring2169 字 (约 9 分钟)
52
Eli Lilly’s VERVE-102 gene therapy reduced PCSK9 by up to 88% and LDL cholesterol by up to 62% in a Phase 1 trial of 35 patients, but data is early-stage; the article mixes optimistic hype with ads, lacking technical depth.
入选理由：VERVE-102基因疗法在35人I期试验中，1.0 mg/kg剂量使PCSK9降低88%、LDL降低62%
FeaturedArticle#Gene Therapy#PCSK9#Eli Lilly#Clinical Trial英文